文献
J-GLOBAL ID:201902285641612728
整理番号:19A1863211
再発進行性尿路上皮癌におけるペムブロリズマブ対パクリタキセル,ドセタキセルまたはビンフルニンの第III相無作為化試験KEYNOTE-045: 2年以上の追跡結果
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
著者 (21件):
FRADET Y.
(Univ. Laval, Quebec City, CAN)
,
BELLMUNT J.
(PSMAR-IMIM Res. Inst., Barcelona, ESP)
,
BELLMUNT J.
(Harvard Medical School Univ., Boston, USA)
,
VAUGHN D. J.
(Perelman Center for Advanced Medicine, Philadelphia, USA)
,
LEE J. L.
(Univ. Ulsan Coll. of Medicine, Seoul, KOR)
,
FONG L.
(Univ. California San Francisco, San Francisco)
,
VOGELZANG N. J.
(Comprehensive Cancer Centers of Nevada, Las Vegas, USA)
,
CLIMENT M. A.
(Fundacion Instituto Valenciano de Oncologia, Valencia, ESP)
,
PETRYLAK D. P.
(Smilow Cancer Hospital at Yale Univ., New Haven)
,
CHOUEIRI T. K.
(Dana-Farber Cancer Inst., Boston, USA)
,
NECCHI A.
(Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITA)
,
GERRITSEN W.
(Radboud Univ. Medical Center, Nijmegen, NLD)
,
GURNEY H.
(Macquarie Univ., NSW, AUS)
,
QUINN D. I.
(Univ. Southern California Norris Comprehensive Cancer Center, Los Angeles, USA)
,
CULINE S.
(Hopital Saint-Louis, Paris, FRA)
,
STERNBERG C. N.
(Weill Cornell Medicine, New York)
,
NAM K.
(Merck & Co., Inc., Kenilworth, USA)
,
FRENKL T. L.
(Merck & Co., Inc., Kenilworth, USA)
,
PERINI R. F.
(Merck & Co., Inc., Kenilworth, USA)
,
DE WIT R.
(Erasmus MC Cancer Inst., Rotterdam, NLD)
,
BAJORIN D. F.
(Memorial Sloan Kettering Cancer Center, New York, USA)
資料名:
Annals of Oncology
(Annals of Oncology)
巻:
30
号:
6
ページ:
970-976
発行年:
2019年06月
JST資料番号:
W0107A
ISSN:
0923-7534
CODEN:
ANONE2
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
イギリス (GBR)
言語:
英語 (EN)